1-3 of 3
Stephane Depil, MD
Close
Sort by
Journal Articles

Abexinostat (S78454/PCI-24781), an Oral Pan-Histone Deacetylas (HDAC) Inhibitor in Patients with Refractory or Relapsed Hodgkin's Lymphoma, Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. Results of a Phase I Dose-Escalation Study in 35 Patients

Franck Morschhauser, MD, PhD, Louis Terriou, MD, Bertrand Coiffier, MD, PhD, Gilles Salles, MD, Ioana Kloos, MD, Nicolas Tavernier, PharmD, Stephane Depil, MD, PhD, Vincent Ribrag, MD
Journal: Blood
Blood (2012) 120 (21): 3643.
https://doi.org/10.1182/blood.V120.21.3643.3643
Published: 2012
Journal Articles

Determination of a HLA II Promiscuous Peptide Cocktail as Potential Vaccine Against EBV Latency II Malignancies.

Stephane Depil, MD, Olivier Morales, Bernard Maillere, PhD, Nadira Delhem, PhD, Violaine Francois, Bertrand Georges, PhD, Franck Morschhauser, MD, Claude Auriault, PhD, Veronique Pancre, PhD
Journal: Blood
Blood (2005) 106 (11): 1478.
https://doi.org/10.1182/blood.V106.11.1478.1478
Published: 2005
Journal Articles

Poor Prognosis of Adult Acute Myeloid Leukemia (AML) with High Level of Evi1 and BAALC Transcript.

Valeria Biggio, Selim Corm, MD, Hugues Leroy, MD, Stephane De Botton, MD, Christophe Roumier, MD, Stephane Depil, MD, Nathalie Philippe, Jean-Luc Lai, MD, PHD, Francis Bauters, MD, PHD, Pierre Fenaux, MD, PHD, Claude Preudhomme, MD, PHD
Journal: Blood
Blood (2004) 104 (11): 2994.
https://doi.org/10.1182/blood.V104.11.2994.2994
Published: 2004